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COMMENTARY
line and progeny should be demonstrated, as well as combinant DNA, propagated cells, etc., should be consulted and met if appropriate. The following study the absence of vector/viral replication or reversion to wild-type virus. The spread of the vector in the host design issues should be considered. which depends on host mechanisms, such as retro-A. Study Phases grade transport, should be determined specifically in the most appropriate animal species, and possible adStudies should follow the model of initial safety asverse consequences considered. sessment (Phase I), followed by establishing early indiThe spatial, temporal, and quantitative analyses of cations of activity and dose/regimen selection (Phase II), transgene expression should be determined and and Phase III for the establishment of the definitive asshould be adequate to expect a useful therapeutic efsessment of safety and efficacy. In initial safety and toxfect in the target condition and one that can likely be icity studies, functional outcome measures should be as measured during a reasonable time period for study.
objective as possible to avoid participant or experiThe consequences of extended, unregulated, and sumenter bias. As much information about physiologic or praphysiologic transgene expression from vectors functional activity as possible should be obtained in should be considered and justified if there is no "safety studies" without compromising the primary means for regulating transgene expression or activity.
aims. In later studies, the best generally accepted rating 4. Ex vivo gene therapy: For the combination of scales in the field should be used to determine clinical gene and cell-based interventions, such as "ex vivo effects, providing data that are understandable to others gene therapy," the rationale should be explained for and which will allow comparison among various estabusing autologous vs. nonautologous cells, isotopic vs.
lished and novel treatments. nonisotopic cell grafts, or the use of xenografts. Any special risks of using the sources should be deter-B. Study Duration mined empirically if possible. All of the safety issues Improvement should be judged significant at a time raised for cell-based treatments should also be conpoint which will be conclusive, consistent with the sidered for cells used for ex vivo gene therapy.
known variability of the condition during the best treatments.
B. Evidence of Beneficial Effects
C. Study Size
The cellular, metabolic, hormonal, behavioral responses, and physiological responses in the host animal Studies should be large enough to meet the study obthat are evoked by the intervention should be consistent jectives. Later studies to assess efficacy should be sized with the intent of the intervention. Any significant syswith consideration of existing data in the field, the size temic effects or other undesirable effects should be conof likely effects, variability of the disease, and effects sidered. Recognition should be given that the relative predicted from animal studies. balance of desired and undesired effects may differ between animal models and human subjects. Persistent ef-
D. Existing Treatments for the Target Condition fects of treatments should be demonstrated in appro-
Should be Considered in the Study Protocol priate animal models for a period that, at the minimum, in the Following Ways would be sufficient to demonstrate and measure a safety 1. The existence or absence of an effective treatment issue or a beneficial effect, considering the known varimay influence the risk/benefit ratio for proceeding ability of the disorder or condition and the precision of with the experiment. For example, a gene therapy the best measurement instruments. Studies should be study for a fatal disease with no treatments might be carried out in the best available model of the disorder.
ethically acceptable with more unknowns and possible toxicity than a similar study for a nonfatal condi-III. CLINICAL STUDIES tion with treatments already available. 2. Can patients be studied without medication for adeThe design and conduct of the study, with regard to the risks and possible benefits, patient consent, risk, conquate periods of time? If this would not work for the entire study, could it be done for fixed evaluation flict of interest disclosures, clinical competency of the investigators and clinicians should be in full compliance periods to eliminate some of the influence of medications on outcome-"drug holidays?" with the regulations of the local jurisdictions in which any portion of the study takes place. Regulations of the 3. Can patients be studied with "fixed doses" of optimized medication, if medications are required? Can U.S. Food and Drug Administration, Institutional Review Boards, and specific regulations related to the prothese reasonably be maintained over sufficient periods of time? curement and use of fetal tissue, transplanted tissue, re-4. Can patients be studied with "optimized" medication
I. Independent Evidence of the Activity of the Studied Intervention Should Be Obtained as a Part of management in addition to the proposed new treatment?
the Study Design 5. Other medications and treatments which are adminisIdeally, a clinical study should include in vivo assesstered during the study period should be minimized ments of the treatment intervention which are indepen-(consistent with patient safety), recorded, reported, dent of the clinical toxicity or functional outcome meaand their impact on study outcome considered.
sures. These might include imaging studies such as PET, SPECT, MRI, fMRI, or cerebrospinal fluid metabolites E. Participant/Subject Selection, Assignment to Study or indicators, if they might provide independent eviGroups, and Statistical Analyses dence of the status of the studied intervention. Although The criteria for participant selection should be dethese measures will not substitute for nor supplant clinifined to give the appropriate population for each phase cal assessments, a clinical study lacking such measures of investigation. Highly homogeneous groups may be may be more difficult to interpret. Every effort should more readily interpretable, but less generalizable to the be made, as a part of the study design and subject confull diversity of the patient population. Narrowly defined sent, to obtain autopsy material for evaluation in the groups may be safer in initial studies, but may not adeevent of the death of a research subject. A plan for how quately assess safety in the broad patient population. these samples will be obtained and studied, under the Consideration should be given in each phase to exclude difficult conditions which are likely, should be included conditions which would confound interpretation or be as a part of the research protocol. likely to suffer excessive adverse events during the study. Subjects should be randomly assigned to active J. Patient Informed Consent or control groups. Plans for data collection and statistical analyses should be included in the study design, and Each subject involved in a clinical study should give data management resources should be adequate for all appropriate consent for participation in the study, being aspects of the studies.
fully informed as to whether the study aims to produce basic scientific knowledge, disease-specific knowledge,
F. Control or Comparison Groups
or potentially individual therapeutic benefit to the particThe clinical study should include controls or comparipant, as well as an idea of the possible negative outison groups and unbiased procedures, depending upon comes. This written consent should meet the standards the stage of the study. Control groups that would be and be approved by the Institutional Review Board of ideal for animal studies might be inappropriate for huthe institution. man studies and vice versa. Possible experimental controls might include the use of sham surgery or "imitation IV. CONSIDERATIONS RELATED TO operation" as a means to control bias. Studies should CONFLICTS OF INTEREST minimize harm to participants whenever possible, consistent with achieving an unbiased assessment of Commercial patentable interests should not operate to outcome.
the detriment of the free sharing of scientific information and the adherence to these goals and considerations.
G. Immune Problems and Rejection
The ASNTR believes that it is in the best interest of Since many currently considered treatment strategies society and of patients that studies be carried out in the carry the risk of producing an immune response in the best manner possible, that results, both positive and negrecipient, the research plan should consider how an imative, are communicated by publication after a reasonmune response would be measured and prevented and able limited period of notification to allow the protection how it would impact on study outcome.
of new intellectual property. Financial support for and potential conflicts of interest by ASNTR investigators H. Assessment Methods Should Be Comparable should be fully disclosed during publication or presentato Other Studies in the Field tion of data. Such support or potential conflicts include the ownership of patent interests, stock or stock options New studies should use comparable assessment methods to those of other investigators and to standard studvalued at more than $10,000, paid consultantships, or membership in Scientific Advisory Boards of companies ies of the target condition. Additional, perhaps improved, methods are not precluded, but there are which might benefit from the study. The Society, in addition, supports the Ethical Guidelines of the Society for significant disadvantages for significant progress if the various studies cannot be meaningfully compared.
Neuroscience.
